ARTICLE | Deals
Seeing high potential for antipsychotic, J&J buys Intra-Cellular for $14.6B
Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years
January 13, 2025 11:49 PM UTC
Five years after Intra-cellular’s launch of antipsychotic therapy Caplyta, the drug is now set to become a growth driver in J&J’s portfolio via its $14.6 billion acquisition of the biotech.
The addition of Caplyta could lead to a projected $5 billion peak sales boost for Johnson & Johnson (NYSE:JNJ), whose neuroscience division has made shrinking contributions to the pharma’s top line in recent years, trailing oncology and immunology...